These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7252814)

  • 1. Statistical simulation study of new proposed uniformity requirement for bioequivalency studies.
    Haynes JD
    J Pharm Sci; 1981 Jun; 70(6):673-5. PubMed ID: 7252814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of moment analysis in assessing rates of absorption for bioequivalency studies.
    Jackson AJ; Chen ML
    J Pharm Sci; 1987 Jan; 76(1):6-9. PubMed ID: 3585726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of metabolites for drugs that undergo nonlinear first-pass effect: impact on bioequivalency assessment using single-dose simulations.
    Braddy AC; Jackson AJ
    J Pharm Sci; 2010 Jan; 99(1):515-23. PubMed ID: 19670465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
    Tsong Y; Dong X; Shen M; Lostritto RT
    J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of selection bias in estimates of relative bioavailability and intrasubject variability from bioequivalence evaluations.
    Wang Y
    J Biopharm Stat; 2000 Aug; 10(3):407-24. PubMed ID: 10959920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On TIER method for assessment of individual bioequivalence.
    Ju HL
    J Biopharm Stat; 1997 Mar; 7(1):63-85. PubMed ID: 9056589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scale effect in bioequivalence evaluations.
    Wang Y; Eradiri O; Odidi I; Geng W; Odidi A; Muhuri G
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):534-9. PubMed ID: 9799057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence approaches for highly variable drugs and drug products.
    Haidar SH; Davit B; Chen ML; Conner D; Lee L; Li QH; Lionberger R; Makhlouf F; Patel D; Schuirmann DJ; Yu LX
    Pharm Res; 2008 Jan; 25(1):237-41. PubMed ID: 17891552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On Statistical Approaches for Demonstrating Analytical Similarity in the Presence of Correlation.
    Yang H; Novick S; Burdick RK
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):547-559. PubMed ID: 27325594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling and simulation of biopharmaceutical performance.
    Zhang X; Lionberger RA
    Clin Pharmacol Ther; 2014 May; 95(5):480-2. PubMed ID: 24747237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.
    Zhang N; Yang J; Chow SC; Chi E
    J Biopharm Stat; 2014; 24(6):1239-53. PubMed ID: 25036940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot trial for the assessment of relative bioavailability in generic drug product development: statistical power.
    Wang Y; Zhou S
    J Biopharm Stat; 1999 Mar; 9(1):179-87. PubMed ID: 10091917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Uniformity of Scored and Unscored Tablets: Application of the FDA Tablet Scoring Guidance for Industry.
    Ciavarella AB; Khan MA; Gupta A; Faustino PJ
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):523-532. PubMed ID: 27974592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RSD requirement for different sample size for blend sampling.
    Saranadasa H
    Drug Dev Ind Pharm; 2000 Nov; 26(11):1213-6. PubMed ID: 11068696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceptance Probability (P a) Analysis for Process Validation Lifecycle Stages.
    Alsmeyer D; Pazhayattil A; Chen S; Munaretto F; Hye M; Sanghvi P
    AAPS PharmSciTech; 2016 Apr; 17(2):516-22. PubMed ID: 26024723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of blend uniformity and content uniformity based on 2003 stratified sampling guidance and 1999 blend uniformity analysis guidance: product A.
    Howard-Sparks M; Gawlikowski A;
    PDA J Pharm Sci Technol; 2004; 58(4):222-30. PubMed ID: 15368992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geometric mean ratio-dependent scaled bioequivalence limits with leveling-off properties.
    Karalis V; Macheras P; Symillides M
    Eur J Pharm Sci; 2005 Sep; 26(1):54-61. PubMed ID: 15955680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.